Compare DexCom, Inc. (DXCM) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Morgan Stanley — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Morgan Stanley trades at $189.1 (market cap $294.39B). The key difference: Morgan Stanley is far larger — about 9.2× DexCom, Inc.'s market cap, and Morgan Stanley pays a 2.45% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Morgan Stanley for 93 Days on average.
| DXCM | MS | |
|---|---|---|
Market Cap | $31.86B | $294.39B |
Volume | 3,607,070 | 5,836,423 |
Sector | Health | Financials |
52-Week High | $92.34 | $228.42 |
52-Week Low | $54.84 | $151.86 |
Typical Hold Time | 62 Days | 93 Days |
Enterprise Value | $31.32B | $660.04B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.
The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
